Skip to main content
. Author manuscript; available in PMC: 2018 Jul 10.
Published in final edited form as: Cancer Lett. 2017 Apr 10;398:46–51. doi: 10.1016/j.canlet.2017.04.004

Figure 2. RhoA and paxillin independently contribute to the cell migration phenotype but only paxillin is involved in tube formation defects in siDLC1 HUVECs.

Figure 2

(A) Representative images of transwell cell migration (upper) or tube formation (lower) of HUVECs treated with indicated siRNAs and bar graphs of data from triplicate experiments. *, P < 0.05 (B) Cell lysates isolated from HUVECs treated with indicated siRNAs were immunoblotted with paxillin or GAPDH antibodies (left) or were used for measuring RhoA activities by Rho G-LISA activation assay (right)(N=3).